Mounjaro 10 mg/0.5 mL pre-filled single-dose pen
Mounjaro® (tirzepatide) is a prescription medication used to improve blood sugar control in adults with type 2 diabetes. It is administered once weekly via a pre-filled, single-use pen and is part of a treatment plan that includes diet and exercise. The 10 mg dose is typically used as part of a titration schedule for patients progressing toward therapeutic goals.
Tirzepatide is a dual GIP and GLP-1 receptor agonist, meaning it mimics two natural hormones involved in glucose metabolism. This dual action helps stimulate insulin release, reduce glucagon levels, slow gastric emptying, and promote a feeling of fullness, which can support weight loss as well as improved glycemic control.
Dosage and Administration:
Each pen contains 10 mg of tirzepatide in 0.5 mL of solution, designed for subcutaneous injection in the abdomen, thigh, or upper arm. Mounjaro is injected once weekly, on the same day each week, with or without food. Patients should rotate injection sites to minimize irritation. The pen is ready to use and does not require mixing or dose setting.
Storage Information:
Keep refrigerated between 36°F and 46°F (2°C to 8°C). If necessary, the pen may be stored at room temperature (not exceeding 86°F or 30°C) for up to 21 days. Do not freeze.
Safety Considerations:
Mounjaro is not recommended for people with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Common side effects include nausea, vomiting, diarrhea, and decreased appetite, particularly during dose escalation. More serious risks, although rare, include pancreatitis, gallbladder problems, kidney injury, and potential thyroid tumors.
Patient Use:
This 10 mg dose is often prescribed after initial titration with lower doses such as 2.5 mg, 5 mg, or 7.5 mg. It may be used as a maintenance dose or as a step toward the maximum strength of 15 mg, depending on individual treatment goals and tolerance.
Reviews
There are no reviews yet.